VRDN Viridian Therapeutics, Inc.
$24.27▲ +0.75%
Healthcare
Other
After hours
$24.21▼ -0.27%
Oct 28, 4:46 PM ET
Volume 1.41M
Avg Volume (10D) 2.19M
Key Metrics & Fundamentals
Market Cap
$2.75B
P/E Ratio
–
Div Yield
0.00%
52W Range
13.18 - 34.29
% vs 50 MA
12.09%
% vs 200 MA
11.14%
RSI-14
69.0
MACD Histogram
+0.6300
Beta (1Y vs SPY)
0.98
Free Cash Flow
-$106.63M
Gross Rev
$284,000
Gross Profit
$284,000
EBITDA
-$117.51M
COGS
–
Operating Exp
$126.55M
Operating Income
-$126.27M
EBIT
-$126.27M
Pretax Income
-$127.12M
Net Income
-$127.12M
EPS (Diluted)
-1.05
Price & Volume History
Loading chart…
Recent News
How FDA Approval Will Impact Viridian Therapeutics Stock
Simply Wall St. · Oct 27, 2026 2:08 PM ET
Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026
Business Wire · Oct 20, 2026 4:00 PM ET
Viridian Therapeutics (VRDN) Stock May Look Stretched Against Its Sales Base
Simply Wall St. · Oct 16, 2026 8:12 PM ET
Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says
MT Newswires · Sep 22, 2026 11:45 AM ET
RBC Raises Price Target on Viridian Therapeutics to $38 From $36, Keeps Outperform, Speculative Risk
MT Newswires · Sep 22, 2026 6:39 AM ET
Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
Business Wire · Sep 2, 2026 4:00 PM ET
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says
MT Newswires · Aug 7, 2026 12:05 PM ET
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating
MT Newswires · Aug 7, 2026 9:28 AM ET
Wedbush Adjusts PT on Viridian Therapeutics to $41 From $43, Maintains Outperform Rating
MT Newswires · Aug 6, 2026 9:43 AM ET
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Business Wire · Aug 6, 2026 7:01 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VRDN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.